Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Hepatitis
 More »

  • AbbVie Expands Galapagos Collaboration to Include Crohn's Disease
    ... AbbVie's pipeline includes mid- to late-stage clinical programs for diseases that include hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, ...
    5-17-2013
  • AZ Giving Way to Early-Stage Biopharmas in Cheshire
    These include the growing threat of drug-resistant superbugs like MRSA, as well as conditions such as influenza, hepatitis C, and HIV." Redx Infectives was established last month, ...
    5-7-2013
  • Human iPSC-Derived Hepatocytes
    ... Hepatitis C Figure 3. iCell Hepatocytes demonstrate key functional markers and ... Data are courtesy of Hoffmann-La Roche. Hepatitis viral infections, both HCV and HBV, ...
    5-1-2013
  • Ascletis Obtains Chinese Rights to Janssen HIV Treatment
    (danoprevir), a clinical-stage hepatitis C protease inhibitor being developed with Roche. ... drug danoprevir in China for hepatitis-C virus. "Based on research to date, we ...
    4-30-2013
  • Enzon Gives Up Hope to Sell
    Enzon's revenues consist of royalties on seven products, the majority of which come from sales of PegIntron (Peginterferon alfa-2b), the hepatitis C virus drug made by Merck & Co. ...
    4-24-2013
  • NanoString Nabs License to Liver Cancer Gene Signature
    cancer, hepatocellular carcinoma (HCC), or with hepatitis C-related early-stage cirrhosis. ... also identifies those patients with hepatitis C-related early-stage cirrhosis who have ...
    4-17-2013
  • Advances in RNAi Tools and Technologies
    ... Arrowhead is pursuing this style of DPC formulation with intravenous delivery of siRNA-mediated knockdown of hepatitis B virus, in which the modified polymers and siRNA cargo are ...
    4-15-2013
  • Roche, Ascletis to Develop HCV Drug in China
    and protease inhibitor danoprevir in China for the treatment of hepatitis C virus (HCV). ... (DAAs) are currently available for hepatitis C in China," added Jinzi J. Wu, Ph.D., ...
    4-15-2013
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    set back by the costly failure of a hepatitis C candidate and the looming loss of ... year for $2.5 billion, with the goal of bringing a successful hepatitis C drug to market. ...
    4-8-2013
  • BMS, Vertex Plan Phase II Studies of Hep C Combo Therapy
    combination therapy designed to fight hepatitis C by wedding BMS' investigational NS5A ... regimens in people with multiple hepatitis C genotypes and in people with ...
    4-5-2013
  • Literature Review: A Flying Drop Becomes a Hanging Drop
    HCV, hepatitis C virus; HIV, human immunodeficiency virus; RT, reverse transcriptase; ITK, interleukin 2-inducible T-cell kinase. The authors showed that the majority of the 284 ...
    4-4-2013
  • Spectrum to Develop Ligand's PG-Free Melphalan
    ... patients for a range of diseases including idiopathic thrombocytopenic purpura (ITP), multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, and osteoporosis. ...
    3-14-2013
  • Small Firms Look Optimistically to Future
    Late-stage projects are under way for cystic fibrosis, hepatitis C, and autoimmune disease and, Dr. Leiden added, "early-stage research has an interesting molecule for genetic and ...
    3-1-2013
  • Addressing Unmet Medical Needs with Complex Carbohydrate Chemistry
    ... disease (ALS), septic shock, liver cirrhosis, chronic hepatitis, pancreatitis, diabetes, acute or critical limb ischemia, gangrene, chronic pressure ulcers, and many others. ...
    2-28-2013
  • Taconic to Market Yecuris' Humanized Animal Models
    and the ability to become infected with human pathogens and viruses like malaria and hepatitis. "Taconic and Yecuris are coming together to provide the knowledge and materials ...
    2-25-2013
  • More »

    Journal Articles

  • Hepatic Differentiation of Human Embryonic Stem Cells Is Promoted...
    Toshio Miki, Alexander Ring, Jörg Gerlach
    Tissue Engineering, Part C: Methods
    The developmental potential of human embryonic stem cells (hESCs) holds great promise to provide a source of human hepatocytes for use in drug discovery, toxicology, hepatitis ...
  • Serological Prevalence of Hepatitis E Virus in Domestic Animals...
    Yansheng Geng, Chuanbin Wang, Chenyan Zhao, Xiuling Yu, Tim J. Harrison, Kegong Tian, Youchun Wang
    Vector-Borne and Zoonotic Diseases
    Serological Prevalence of Hepatitis E Virus in Domestic Animals and Diversity of Genotype 4 Hepatitis E Virus in China Vector-Borne and Zoonotic Diseases Abstract Pigs have been ...
  • A Bioinformatics Approach to Identify Natural Autoantibodies...
    Nada Vasiljevic, Nevena Veljkovic, Tatjana Kosec, Xue-Zhong Ma, Sanja Glisic, Jelena Prljic, Ana Djordjevic Vujicic, Ljiljana Markovic, Donald R. Branch
    Viral Immunology
    We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the fact that the HCV proteome is characterized by extensive sequence similarities to the human ...
  • Improvement of Neutralizing Activity of Human scFv Antibodies...
    Sae-Gwang Park, Young-Joo Jung, Young-Yi Lee, Cheul-Min Yang, Ik-Jung Kim, Jun-Ho Chung, Ik-Sang Kim, Youn-Jae Lee, Sung-Jae Park, Jeong-Nyeo Lee, Su-Kil Seo, Yong-Hong Park, In-Hak Choi
    Viral Immunology
    Improvement of Neutralizing Activity of Human scFv Antibodies Against Hepatitis B Virus ... fragment (scFv) specific for pre-S1 of hepatitis B virus (HBV) by introducing random ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll